trending Market Intelligence /marketintelligence/en/news-insights/trending/qke-qkjosuffm3t6ssj2bw2 content esgSubNav
In This List

Bluebird Bio closes $632.5M common stock offering

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Bluebird Bio closes $632.5M common stock offering

Bluebird Bio Inc. closed an underwritten public offering for gross proceeds of about $632.5 million.

The Cambridge, Mass.-based biotechnology company sold 3,892,308 common shares at $162.50 apiece. Shares issued include 507,692 common shares sold as part of the full exercise of the underwriters' overallotment option.

Goldman Sachs & Co. LLC, BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen acted as joint book-running managers, with Wells Fargo Securities as co-manager of the offering.

Bluebird Bio develops gene therapies for severe genetic diseases and cancer.